AIMS: Activation of vascular GPER has been linked to vasodepressor effects in animals. However, the significance of GPER regulation on chronic blood pressure control in humans is unknown. METHODS: To examine this question we determined the functional significance of expression of a common missense single nucleotide variant of GPER, P16L in vascular smooth muscle cells, and its association with blood pressure in humans. Further, to validate the importance of carrying GPER P16L in the development of hypertension we assessed allele frequency in a cohort of hard-to-treat hypertensive patients referred to a tertiary care clinic. RESULTS: Expression of the GPER P16L variant (V) vs. wild type (WT) in rat aortic vascular smooth muscle cells, was associated with a significant decrease in G1 (1 μm, a GPER agonist)-mediated ERK phosphorylation (slope of the function of G1-stimulated ERK phosphorylation: GPER content WT: 16.2, 95% CI 9.9, 22.6; V: 5.0, 95% CI 1.0, 9.0; P < 0.005) and apoptosis (slope of the function of G1-stimulated apoptosis: GPER content: WT: 4.4, 95% CI: 3.4, 5.4; V: 2.5, 95% CI 1.6, 2.3 P < 0.005). Normotensive female subjects, but not male subjects, carrying this hypofunctional variant (allele frequency 22%) have increased blood pressure [mean arterial pressure: P16/P16: 80 ± 1 mmHg (n = 204) vs. P16L carriers: 82 ± 1 mmHg (n = 127), 95% CI for difference: 0.6, 4.0 mmHg, P < 0.05], [systolic blood pressure: P16/P16: 105 ± 1 mmHg vs. P16L carriers: 108 ± 1 mmHg, 95% CI for difference:1.0, 5.1 mmHg, P < 0.05], [diastolic blood pressure: P16/P16: 66 ± 0.5 mmHg vs. P16L carriers 68 ± 0.7, 95% CI for difference: 0.2, 3.6 mmHg, P < 0.05]. Further, the P16L allele frequency was almost two-fold higher in female vs. male hypertensive patients (31% vs. 16%, allele ratio 0.5, 95% CI 0.32, 0.76, P < 0.05). CONCLUSIONS: The common genetic variant, GPER P16L, is hypofunctional and female carriers of this allele have increased blood pressure. There was an increased prevalence in a population of hard-to-treat hypertensive female patients. Cumulatively, these data suggest that in females, impaired GPER function might be associated with increased blood pressure and risk of hypertension.
AIMS: Activation of vascular GPER has been linked to vasodepressor effects in animals. However, the significance of GPER regulation on chronic blood pressure control in humans is unknown. METHODS: To examine this question we determined the functional significance of expression of a common missense single nucleotide variant of GPER, P16L in vascular smooth muscle cells, and its association with blood pressure in humans. Further, to validate the importance of carrying GPERP16L in the development of hypertension we assessed allele frequency in a cohort of hard-to-treat hypertensivepatients referred to a tertiary care clinic. RESULTS: Expression of the GPERP16L variant (V) vs. wild type (WT) in rat aortic vascular smooth muscle cells, was associated with a significant decrease in G1 (1 μm, a GPER agonist)-mediated ERK phosphorylation (slope of the function of G1-stimulated ERK phosphorylation: GPER content WT: 16.2, 95% CI 9.9, 22.6; V: 5.0, 95% CI 1.0, 9.0; P < 0.005) and apoptosis (slope of the function of G1-stimulated apoptosis: GPER content: WT: 4.4, 95% CI: 3.4, 5.4; V: 2.5, 95% CI 1.6, 2.3 P < 0.005). Normotensive female subjects, but not male subjects, carrying this hypofunctional variant (allele frequency 22%) have increased blood pressure [mean arterial pressure: P16/P16: 80 ± 1 mmHg (n = 204) vs. P16L carriers: 82 ± 1 mmHg (n = 127), 95% CI for difference: 0.6, 4.0 mmHg, P < 0.05], [systolic blood pressure: P16/P16: 105 ± 1 mmHg vs. P16L carriers: 108 ± 1 mmHg, 95% CI for difference:1.0, 5.1 mmHg, P < 0.05], [diastolic blood pressure: P16/P16: 66 ± 0.5 mmHg vs. P16L carriers 68 ± 0.7, 95% CI for difference: 0.2, 3.6 mmHg, P < 0.05]. Further, the P16L allele frequency was almost two-fold higher in female vs. male hypertensivepatients (31% vs. 16%, allele ratio 0.5, 95% CI 0.32, 0.76, P < 0.05). CONCLUSIONS: The common genetic variant, GPERP16L, is hypofunctional and female carriers of this allele have increased blood pressure. There was an increased prevalence in a population of hard-to-treat hypertensive female patients. Cumulatively, these data suggest that in females, impaired GPER function might be associated with increased blood pressure and risk of hypertension.
Authors: Henian Cao; Eric van der Veer; Matthew R Ban; Anthony J G Hanley; Bernard Zinman; Stewart B Harris; T Kue Young; J Geoffrey Pickering; Robert A Hegele Journal: J Clin Endocrinol Metab Date: 2004-02 Impact factor: 5.958
Authors: Chetana M Revankar; Daniel F Cimino; Larry A Sklar; Jeffrey B Arterburn; Eric R Prossnitz Journal: Science Date: 2005-02-10 Impact factor: 47.728
Authors: Brenda R Hemmelgarn; Finlay A McAllister; Martin G Myers; Donald W McKay; Peter Bolli; Carl Abbott; Ernesto L Schiffrin; Steven Grover; George Honos; Marcel Lebel; Karen Mann; Thomas Wilson; Brian Penner; Guy Tremblay; Sheldon W Tobe; Ross D Feldman Journal: Can J Cardiol Date: 2005-06 Impact factor: 5.223
Authors: Harshal Waghulde; Xi Cheng; Sarah Galla; Blair Mell; Jingwei Cai; Shondra M Pruett-Miller; Guillermo Vazquez; Andrew Patterson; Matam Vijay Kumar; Bina Joe Journal: Hypertension Date: 2018-11 Impact factor: 10.190
Authors: Natalie C Fredette; Eliyah Malik; Marah L Mukhtar; Eric R Prossnitz; Naohiro Terada Journal: Am J Physiol Cell Physiol Date: 2020-08-12 Impact factor: 4.249
Authors: Geetanjali Sharma; Chelin Hu; Daniela I Staquicini; Jonathan L Brigman; Meilian Liu; Franck Mauvais-Jarvis; Renata Pasqualini; Wadih Arap; Jeffrey B Arterburn; Helen J Hathaway; Eric R Prossnitz Journal: Sci Transl Med Date: 2020-01-29 Impact factor: 17.956
Authors: Eman Y Gohar; Rawan N Almutlaq; Elizabeth M Daugherty; Maryam K Butt; Chunhua Jin; Jennifer S Pollock; David M Pollock; Carmen De Miguel Journal: Am J Physiol Regul Integr Comp Physiol Date: 2021-01-06 Impact factor: 3.619